



Immune Deficiency Treatment Centre / Centre de Traitement de l'Immunodéficience
McGill AIDS Centre / Centre SIDA McGill
Montreal General Hospital / Hôpital Général de Montréal
McGill University Health Centre / Centre universitaire de santé McGill
1650 Cedar, Suite A5-140 Montreal, QC H3G 1A4 514-934-8070

A NOVEL HIV INHIBITOR RESEARCH STUDY

Purpose

To test the safety of a new research drug which is being developed to interfere with the process by which HIV targets a specific viral enzyme that is necessary for HIV to multiply. Within this combination therapy study, you will receive either the investigational drug or efavirenz, along with two other anti-HIV medications, tenofovir and lamivudine, to treat your HIV infection.

Entry Criteria

If your viral load (the amount of virus in your blood) is at least 5,000 copies/mL, your CD4 count is at least 100 cells/mm³, and you have taken anti-HIV medications for less than seven (7) days, you may be eligible to participate.

Duration

This is a 48-week triple therapy study, wherein all study medications will be supplied.

Contact Information

For full details of the study, please contact James Vatisas at 514-934-8050 or Nadia Moubarik at 514-934-1934, local 42460.